当前位置:首页 > 产品中心 > 细胞培养基及添加物

细胞培养基及添加物

Heparin Solution

Cell culture supplement

概要
技术资料
数据及文献

概要

Heparin is a mucopolysaccharide with anticoagulant properties. It supports the binding of fibroblast growth factor (FGF) to its receptor and increases the stability of FGF. Heparin is used together with epidermal growth factor (EGF) and FGF in NeuroCult™ media for the culture of embryonic rat or adult human neural stem and progenitor cells, and adult mouse neural stem and progenitor cells. For complete instructions, refer to the Technical Manual: In Vitro Proliferation and Differentiation of Neural Stem and Progenitor Cells Using NeuroCult™ (Human; Document #28724 or Mouse/Rat; Document #28725), available at www.stemcell.com or contact us to request a copy.

Heparin Solution is also required as a supplement in various other STEMCELL culture media, including MammoCult™ Human Medium Kit (Catalog #05620), EpiCult™-B Mouse Medium Kit (Catalog #05610), and EC-Cult™-XF Culture Kit (Catalog #08000).

技术资料

Document Type 产品名称 Catalog # Lot # 语言
Product Information Sheet Heparin Solution 07980 All English
Safety Data Sheet Heparin Solution 07980 All English

数据及文献

Publications (1)

Neuro-oncology 2011 SEP Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Bai R-Y et al.

Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive brain cancer, and despite treatment advances, patient prognosis remains poor. During routine animal studies, we serendipitously observed that fenbendazole, a benzimidazole antihelminthic used to treat pinworm infection, inhibited brain tumor engraftment. Subsequent in vitro and in vivo experiments with benzimidazoles identified mebendazole as the more promising drug for GBM therapy. In GBM cell lines, mebendazole displayed cytotoxicity, with half-maximal inhibitory concentrations ranging from 0.1 to 0.3 µM. Mebendazole disrupted microtubule formation in GBM cells, and in vitro activity was correlated with reduced tubulin polymerization. Subsequently, we showed that mebendazole significantly extended mean survival up to 63% in syngeneic and xenograft orthotopic mouse glioma models. Mebendazole has been approved by the US Food and Drug Administration for parasitic infections, has a long track-record of safe human use, and was effective in our animal models with doses documented as safe in humans. Our findings indicate that mebendazole is a possible novel anti-brain tumor therapeutic that could be further tested in clinical trials.
View All Publications